EA2176 Phase 3 Trial Evaluates Opdivo Combination as First-line Treatment for Metastatic Anorectal Cancer
Clinical Design and Progress
Sponsored by the National Cancer Institute (NCI) and conducted by ECOG-ACRIN, EA2176 is a randomized, open-label Phase 3 trial enrolling 205 treatment-naïve patients with metastatic anorectal cancer. It compares a combination of caboplatin and paclitaxel standard chemotherapy with Opdivo (nivolumab) to chemotherapy alone, with progression-free survival (PFS) as the primary endpoint. Enrollment was completed in November 2020, and as of July 2026, follow-up is ongoing after recruitment ended, placing the trial in the pre-registration phase.
Drug Mechanism and Treatment Strategy
Bristol Myers Squibb’s Opdivo is a monoclonal antibody that blocks T-cell programmed cell death protein-1 (PD-1), restoring anti-tumor immune responses as an immune checkpoint inhibitor. Paraplatin (caboplatin) induces DNA cross-linking, and Taxol (paclitaxel) binds to beta-tubulin to disrupt microtubule assembly and inhibit cell division. The experimental arm combines up to six cycles of chemotherapy with nivolumab, followed by nivolumab maintenance for up to two years, aiming to achieve early tumor shrinkage and long-term immune control.
Competitive Landscape and Clinical Benchmark
The direct competitor to this trial is Incyte’s Zynyz (retifanlimab-dlwr), which also targets PD-1 and is being evaluated in the POD1UM-303 Phase 3 trial in combination with caboplatin and paclitaxel. The trial reported a median PFS of 9.3 months versus 7.4 months, a hazard ratio of 0.63, and a p-value of 0.0006. On May 15, 2025, the FDA approved Zynyz in combination for first-line treatment of unresectable locally recurrent or metastatic anorectal squamous cell carcinoma. Consequently, the nature of EA2176 has shifted from evaluating the concept of immune-oncology combination to demonstrating the efficacy, safety, and maintenance therapy competitiveness of nivolumab against the already approved Zynyz.
Regulatory and Commercial Implications
Opdivo received its first FDA approval on December 22, 2014, but anorectal cancer is not included in the 2025 U.S. prescribing information, making the Opdivo combination in EA2176 a Phase 3 development. Zynyz faced a delay in 2021 when the FDA Oncologic Drugs Advisory Committee voted 13 to 4 to defer approval and issued a complete response letter, but it secured approval in 2025 based on confirmatory Phase 3 results. The U.S. anorectal cancer treatment market is projected to grow from approximately USD 500 million in 2024 to USD 1.2 billion by 2034. While the market size of rare cancers is relatively small, the value of expanding Opdivo’s indications to defend its USD 10 billion 2025 revenue remains a significant investment consideration.
EA2176 is a Phase 3 trial with 205 patients evaluating PFS improvement with nivolumab combination, but Incyte’s Zynyz has already secured FDA approval in 2025, establishing a first-mover advantage with caboplatin and paclitaxel combination. Positive results from EA2176 could provide Bristol Myers Squibb with the evidence needed to expand Opdivo’s indications for anorectal cancer and defend its late-stage immunotherapy portfolio. Conversely, if the trial fails to clinically distinguish itself from Zynyz’s Phase 3 results—median PFS of 9.3 months and a hazard ratio of 0.63—the persuasiveness of prescription switching and insurance coverage may weaken. For researchers and industry stakeholders, the reproducibility of PD-1 combination, efficacy in HIV-positive patients and those previously treated with chemoradiation, and the toxicity and cost of up to two years of maintenance therapy are key variables that will determine the real-world adoption rate in the USD 500 million U.S. market.
Source: ClinicalTrials.gov (api_ct)